These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23891501)

  • 41. Nanogel-based antigen-delivery system for nasal vaccines.
    Yuki Y; Nochi T; Kong IG; Takahashi H; Sawada S; Akiyoshi K; Kiyono H
    Biotechnol Genet Eng Rev; 2013; 29():61-72. PubMed ID: 24568253
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Archaeosomes with encapsulated antigens for oral vaccine delivery.
    Li Z; Zhang L; Sun W; Ding Q; Hou Y; Xu Y
    Vaccine; 2011 Jul; 29(32):5260-6. PubMed ID: 21609747
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Designer outer membrane vesicles as immunomodulatory systems - Reprogramming bacteria for vaccine delivery.
    Gnopo YMD; Watkins HC; Stevenson TC; DeLisa MP; Putnam D
    Adv Drug Deliv Rev; 2017 May; 114():132-142. PubMed ID: 28501509
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Yeasts in nanotechnology-enabled oral vaccine and gene delivery.
    Ivanova E
    Bioengineered; 2021 Dec; 12(1):8325-8335. PubMed ID: 34592900
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Liposomal vaccine delivery systems.
    Henriksen-Lacey M; Korsholm KS; Andersen P; Perrie Y; Christensen D
    Expert Opin Drug Deliv; 2011 Apr; 8(4):505-19. PubMed ID: 21413904
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent advances in oral vaccine development: yeast-derived β-glucan particles.
    De Smet R; Allais L; Cuvelier CA
    Hum Vaccin Immunother; 2014; 10(5):1309-18. PubMed ID: 24553259
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fully mobilizing host defense: building better vaccines.
    Raychaudhuri S; Rock KL
    Nat Biotechnol; 1998 Nov; 16(11):1025-31. PubMed ID: 9831030
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mucosal vaccination and therapy with genetically modified lactic acid bacteria.
    Wells J
    Annu Rev Food Sci Technol; 2011; 2():423-45. PubMed ID: 22129390
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Delivery systems: a vaccine strategy for overcoming mucosal tolerance?
    Mann JF; Acevedo R; Campo JD; Pérez O; Ferro VA
    Expert Rev Vaccines; 2009 Jan; 8(1):103-12. PubMed ID: 19093777
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lactic acid bacteria - promising vaccine vectors: possibilities, limitations, doubts.
    Szatraj K; Szczepankowska AK; Chmielewska-Jeznach M
    J Appl Microbiol; 2017 Aug; 123(2):325-339. PubMed ID: 28295939
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro antigen measurement and potency tests: challenges encountered during method development...and lessons learned.
    Kubiak V
    Dev Biol (Basel); 2012; 134():83-91. PubMed ID: 22888599
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Delivery systems for molecular vaccination.
    Sheikh NA; al-Shamisi M; Morrow WJ
    Curr Opin Mol Ther; 2000 Feb; 2(1):37-54. PubMed ID: 11249651
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current status and potential application of ISCOMs in veterinary medicine.
    Morein B; Hu KF; Abusugra I
    Adv Drug Deliv Rev; 2004 Jun; 56(10):1367-82. PubMed ID: 15191787
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Delivery of antigens used for vaccination: recent advances and challenges.
    Scherliess R
    Ther Deliv; 2011 Oct; 2(10):1351-68. PubMed ID: 22826888
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vaccinia virus as a vaccine delivery system for marsupial wildlife.
    Cross ML; Fleming SB; Cowan PE; Scobie S; Whelan E; Prada D; Mercer AA; Duckworth JA
    Vaccine; 2011 Jun; 29(28):4537-43. PubMed ID: 21570435
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The potential of oral vaccines for disease control in wildlife species.
    Cross ML; Buddle BM; Aldwell FE
    Vet J; 2007 Nov; 174(3):472-80. PubMed ID: 17113798
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nanoparticles for nasal vaccination.
    Csaba N; Garcia-Fuentes M; Alonso MJ
    Adv Drug Deliv Rev; 2009 Feb; 61(2):140-57. PubMed ID: 19121350
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Crossing the barrier: Targeting epithelial receptors for enhanced oral vaccine delivery.
    Devriendt B; De Geest BG; Goddeeris BM; Cox E
    J Control Release; 2012 Jun; 160(3):431-9. PubMed ID: 22353618
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Particle-based vaccines for transcutaneous vaccination.
    Combadière B; Mahé B
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):293-315. PubMed ID: 17915323
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antigen uptake and immune responses after oral vaccination.
    Quentel C; Vigneulle M
    Dev Biol Stand; 1997; 90():69-78. PubMed ID: 9270836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.